Gene Editing is the ability to make highly specific changes in the DNA sequence of a living organism, essentially customizing its genetic makeup. It demonstrates great potential in gene research, gene therapy and genetic improvement. The Gene Editing concept includes major US-listed companies whose businesses are involved in gene editing.
- 1439.588
- +29.320+2.08%
Critical Insights From Sangamo Therapeutics Analyst Ratings: What You Need To Know
Sangamo Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA), Liquidia Technologies (LQDA) and Pacific Biosciences (PACB)
Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX), Bluebird Bio (BLUE) and Nuvalent (NUVL)
Wolfe Research Adjusts Price Target on Vertex Pharmaceuticals to $520 From $497
Analysts Have Conflicting Sentiments on These Healthcare Companies: Mersana Therapeutics (MRSN), Insulet (PODD) and Crispr Therapeutics AG (CRSP)
Analysts Offer Insights on Healthcare Companies: Aura Biosciences Inc (AURA), Iovance Biotherapeutics (IOVA) and Intellia Therapeutics (NTLA)
Analysts Are Bullish on These Healthcare Stocks: Apellis Pharmaceuticals (APLS), TScan Therapeutics (TCRX)
Caribou Biosciences Analyst Ratings
Caribou Biosciences (CRBU) Receives a Buy From Bank of America Securities
Stifel Nicolaus Sticks to Their Hold Rating for Crispr Therapeutics AG (CRSP)
Analysts' Opinions Are Mixed on These Healthcare Stocks: Caribou Biosciences (CRBU) and Mettler-Toledo (MTD)
Analysts' Opinions Are Mixed on These Healthcare Stocks: Beam Therapeutics (BEAM), Cormedix (CRMD) and Applied Therapeutics (APLT)
Intellia Therapeutics Analyst Ratings
CRISPR Therapeutics Analyst Ratings
Intellia Therapeutics Analyst Ratings
Oppenheimer Adjusts CRISPR Therapeutics Price Target to $95 From $102, Maintains Outperform Rating
Intellia Therapeutics: A Promising Buy Rating Supported by Trial Success and Strong Financials
Analysts' Opinions Are Mixed on These Healthcare Stocks: Catalyst Pharma (CPRX), Xenon (XENE) and Intellia Therapeutics (NTLA)
Bluebird Bio (BLUE) Receives a Hold From RBC Capital